Milk Thistle for NAFLD / MASLD

Verdict: Lowers liver enzymes, but unproven for the disease

Milk thistle (silymarin) reliably nudges down liver enzymes in fatty liver disease, but the two best biopsy-based trials found it did not actually improve the liver tissue itself. Treat it as an unproven adjunct, not a treatment for NAFLD/MASLD.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The evidence splits cleanly along the line between a blood marker and the actual disease. Three meta-analyses agree that silymarin meaningfully lowers the liver enzymes ALT and AST: the largest pooled 26 trials and 2,375 patients (PMID 38579127), supported by two smaller analyses (PMID 29245314; PMID 33418491). But ALT/AST are surrogate markers, and the 2021 review (PMID 33418491) explicitly cautions that this enzyme drop has not been shown to translate into real tissue improvement.

That harder test is where milk thistle falls short. The two best-designed trials that biopsied the liver both missed their primary endpoints: the NIH/NCCIH-funded multicenter SyNCH trial saw no benefit over placebo (PMID 31536511, p=0.79), and a Malaysian trial likewise failed its primary histology endpoint (PMID 28419855, p=0.467), with only an exploratory secondary fibrosis signal. Because the outcome that matters stays unproven, the grade is a weak C rather than a clear pass.

Authorities reinforce the caution. The Mayo Clinic states milk thistle 'hasn't proved effective for improving liver health'; the US FDA declined a GRAS determination and has no approved liver claim; and EFSA has authorized no such claim. The supplement is generally well tolerated, but for NAFLD the proven path remains weight loss and diet, not silymarin.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.29
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.421
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
PMID: 38579127 2024 統合分析 n = 2,375
Finding: Across 26 RCTs silymarin significantly reduced ALT (SMD -12.39, 95% CI -19.69 to -5.08) and AST (SMD -10.97, 95% CI -15.51 to -6.43), lowered fatty liver index (SMD -6.64, 95% CI -10.59 to -2.69) and fatty liver score (SMD -0.51, 95% CI -0.69 to -0.33), and improved hepatic steatosis (OR 3.25, 95% CI 1.80 to 5.87).
Effect size: SMD ALT -12.39; SMD AST -10.97; steatosis improvement OR 3.25
View on PubMed
The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials
PMID: 29245314 2017 統合分析 n = 587
Finding: Pooled analysis of 8 RCTs (587 patients) showed silymarin reduced AST (MD -6.57, 95% CI -10.03 to -3.12, p=0.0002) and ALT (MD -9.16, 95% CI -16.24 to -2.08, p=0.01); silymarin-monotherapy subgroup showed AST MD -5.44 and ALT MD -5.08.
Effect size: MD AST -6.57 U/L; MD ALT -9.16 U/L
View on PubMed
Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis
PMID: 33418491 2021 統合分析
Finding: Silymarin produced a statistically significant greater reduction in transaminase levels versus placebo, independent of weight loss; authors stress that whether this enzyme reduction translates to histologic improvement remains unconfirmed and call for well-designed trials.
🟠 Limited quality Effect size: significant transaminase reduction; numeric pooled estimate not reported in abstract
View on PubMed
Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial (SyNCH NASH)
PMID: 31536511 2019 RCT (double-blind) n = 78
Finding: Largely null NCCIH-funded trial: primary endpoint reached by 4/27 (15%) at 700 mg, 5/26 (19%) at 420 mg, and 3/25 (12%) on placebo (p=0.79); fibrosis stage improved most in the placebo arm. Central pathology review found 63% of enrolled patients did not meet histologic entry criteria.
Government Effect size: no significant difference vs placebo (p=0.79)
View on PubMed
A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
PMID: 28419855 2017 RCT (double-blind) n = 99
Finding: Primary endpoint NOT met: 32.7% silymarin vs 26.0% placebo achieved >=30% NAS reduction (p=0.467). Secondary signal: more silymarin patients had fibrosis reduction of >=1 point on histology (22.4% vs 6.0%, p=0.023) and improved liver stiffness; significance of these secondary endpoints is exploratory.
Effect size: primary NS; secondary fibrosis reduction 22.4% vs 6.0%
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Notice does not provide a basis for a GRAS determination source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
水飛薊素(silymarin)是水飛薊種子所提煉出的多種類黃酮總稱,被認為具有保肝的功效。在某些國家作為保肝的處方藥品,有些國家則作為保健食品。 source↗
L4e WHO
Neutral
Fructus Silybi Mariae consists of the dried ripe fruits, freed from the pappus, of Silybum marianum (L.) Gaertn. (Asteraceae). [WHO Monographs on Selected Medicinal Plants, Volume 2, 2002] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
While milk thistle is generally safe, it hasn't proved effective for improving liver health. source↗
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-nafld-INT-milk-thistle-001 繁體中文版 →